<DOC>
	<DOCNO>NCT00001044</DOCNO>
	<brief_summary>PRIMARY : To examine safety potential improvement immune response elicit combine rsgp120/HIV-1MN adjuvant QS-21 . SECONDARY : To examine role alum vaccine/adjuvant formulation ; determine optimal dose ratio vaccine adjuvant ; obtain initial information optimal schedule administration . AS PER AMENDMENT 07/02/97 : To determine ability immunization rsgp120/HV-1MN combination QS21 without alum induce HIV-1 envelope-specific delayed-type hypersensitivity ( DTH ) response volunteer undergo rsgp120/MN skin test . Immune response HIV-uninfected individual receive subunit envelope vaccine formulate alum adjuvant suggest functional antibody capable neutralize HIV-1 vitro may induce , titer relatively low comparison measure individual natural HIV-1 infection . These limitation might overcome addition substitution suitable adjuvant QS-21 .</brief_summary>
	<brief_title>A Phase I , Multicenter , Randomized , Double-Blind , Placebo-Controlled HIV-1 Vaccine Trial Evaluate Safety Immunogenicity rgp120/HIV-1MN ( Genentech ) Combination With QS21 Adjuvant and/or Alum Healthy Adults .</brief_title>
	<detailed_description>Immune response HIV-uninfected individual receive subunit envelope vaccine formulate alum adjuvant suggest functional antibody capable neutralize HIV-1 vitro may induce , titer relatively low comparison measure individual natural HIV-1 infection . These limitation might overcome addition substitution suitable adjuvant QS-21 . Volunteers randomize 20 treatment arm contain four patient . rsgp120/HIV-1MN administer four dose level : 0 , 100 , 300 , 600 mcg , QS-21 adjuvant administer three dose level : 0 , 50 , 100 mcg . Some subject cohort receive alum vaccine formulation . Sixty volunteer receive injection month 0 , 1 , 10 , 20 volunteer receive injection month 0 , 1 , 6 . AS PER AMENDMENT 07/02/97 : All consent volunteer receive three immunization test DTH response HIV-1 envelope use intradermal MN rsgp120 . Follow-up extend 56 day administration intradermal injection .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>Inclusion Criteria Subjects must : Normal history physical exam . HIV negativity ELISA within 6 week immunization . CD4 count &gt; = 400 cells/mm3 . Normal urine dipstick esterase nitrite . Exclusion Criteria Coexisting Condition : Subjects follow symptoms condition exclude : Hepatitis B surface antigen . Medical psychiatric condition occupational responsibility preclude compliance . Active syphilis . NOTE : Subjects serology document false positive due remote ( &gt; 6 month ) treat infection eligible . Active tuberculosis . NOTE : Subjects positive PPD normal chest xray show evidence TB require isoniazid therapy eligible . Subjects follow prior condition exclude : History immunodeficiency , autoimmune disease , use immunosuppressive medication . History anaphylaxis serious adverse reaction vaccine . History allergy thimerosal . AS PER AMENDMENT 07/02/97 : History eczema allergictype reaction rsgp120/HIV1MN vaccine ( volunteer undergo DTH test ) . Prior Medication : Excluded : Live attenuate vaccine within 60 day prior study entry . ( NOTE : Medically indicate subunit kill vaccine , influenza pneumococcal , allow give least 2 week prior HIV immunization . ) Experimental agent within 30 day prior study entry . Prior HIV vaccine . AS PER AMENDMENT 07/02/97 : Use systemic steroid past month ( volunteer undergo DTH test ) . Prior Treatment : Excluded : Receipt blood product immunoglobulin within past 6 month . Identifiable highrisk behavior HIV infection determine screen questionnaire , include history injection drug use within past year higher intermediate risk sexual behavior .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Adjuvants , Immunologic</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>